retatrutide creator Eli Lilly and Company's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Retatrutide trifluoroacetate | 2381089-83-2 |
Pay in 4 interest-free payments of $7.14 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11

























